Recombinant Human C4.4A/LYPD3 Protein, CF Summary
Leu31-His286, with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
C4.4A, also known as Ly6/PLAUR domain containing 3 (LYPD-3), is a GPI-linked protein with structural similarity to the urokinase-type plasminogen activator receptor (uPAR) (1). It is a 65 - 100 kDa molecule with variable cell type-specific N- and O-linked glycosylation, and shares 80% amino acid sequence identity with mouse and rat C4.4A (2, 3). Mature human C4.4A contains two uPAR/Ly6 domains and a Ser/Thr/Pro-rich (STP) region that includes a protease sensitive site (4, 5). Proteolytic cleavage following the second uPAR/Ly6 domain generates a 35 - 40 kDa soluble form, while ADAM10 or ADAM17-mediated cleavage within the STP region generates a 90 kDa soluble form (6, 8). Soluble C4.4A can also be shed and released in membrane vesicles (5). C4.4A is expressed in the suprabasal layers of stratified squamous epithelium and is upregulated on migrating keratinocytes during wound healing (6, 7). Its expression is downregulated during the onset of epithelial dysplasia but is subsequently upregulated at the invasive front of melanomas and various carcinomas (2, 6, 5, 9). Metastases derived from these tumors also express high levels of C4.4A (2, 5, 6). The interaction of C4.4A with Laminin 1 and 5 on neighboring cells promotes the adhesion, spreading, and migration of tumor cells (4, 6, 10). C4.4A additionally interacts with Galectin-3 and the anterior gradient proteins AG-2 and AG-3 (10, 11). C4.4A overexpression in non-small cell lung cancer is predictive of increased mortality (12).
- Jacobsen, B. and M. Ploug (2008) Curr. Med. Chem. 15:2559.
- Rosel, M. et al. (1998) Oncogene 17:1989.
- Paret, C. et al. (2007) Br. J. Cancer 97:1146.
- Smith, B.A. et al. (2001) Cancer Res. 61:1678.
- Wurfel, J. et al. (2001) Gene 262:35.5.
- Hansen, L.V. et al. (2008) Int. J. Cancer 122:734.
- Hansen, L.V. et al. (2004) Biochem. J. 380:845.
- Esselens, C.W. et al. (2008) Biol. Chem. 389:1075.
- Seiter, S. et al. (2001) J. Invest. Dermatol. 116:344.
- Paret, C. et al. (2005) Int. J. Cancer 115:724.
- Fletcher, G.C. et al. (2003) Br. J. Cancer 88:579.
- Hansen, L.V. et al. (2007) Lung Cancer 58:260.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human C4.4A/LYPD3 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human C4.4A/LYPD3 Protein, CF and earn rewards!
Have you used Recombinant Human C4.4A/LYPD3 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image